CLAL BIOTECHNOLOGY INDUSTRIES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.1 ILa | -2.80% |
|
+0.22% | +13.60% |
| Sales 2022 | 370K 97.19K 37M | Sales 2023 | 104K 27.32K 10.4M | Capitalization | 62.27M 16.36M 6.23B |
|---|---|---|---|---|---|
| Net income 2022 | -61M -16.02M -6.1B | Net income 2023 | -31M -8.14M -3.1B | EV / Sales 2022 | 331 x |
| Net Debt 2022 | 23.85M 6.26M 2.38B | Net Debt 2023 | 22.4M 5.88M 2.24B | EV / Sales 2023 | 814 x |
| P/E ratio 2022 |
-1.6
x | P/E ratio 2023 |
-2.01
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 34.65% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.80% | ||
| 1 week | +0.22% | ||
| Current month | +7.64% | ||
| 1 month | +2.73% | ||
| 3 months | +21.24% | ||
| 6 months | +1.35% | ||
| Current year | +13.60% |
1 week
44.20
46.90
1 month
40.6046.90
Current year
36.6049.70
1 year
36.6065.00
3 years
36.60267.80
5 years
36.60295.50
10 years
36.601 140.00
| Managers | Title | Age | Since |
|---|---|---|---|
Assaf Segal
CEO | Chief Executive Officer | 51 | 15-06-30 |
Liat Nissan
DFI | Director of Finance/CFO | 46 | - |
Arnon Aharon
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 03-05-08 | |
Yuval Yanai
BRD | Director/Board Member | 71 | 15-11-17 |
Gad Keren
BRD | Director/Board Member | 73 | 20-02-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 45.1 | -2.80% | 16,816 |
| 24-04-24 | 46.4 | +3.57% | 17,970 |
| 24-04-21 | 44.8 | -0.44% | 37,722 |
| 24-04-18 | 45 | +0.22% | 69,840 |
| 24-04-17 | 44.9 | +7.16% | 338,284 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 07:24 am EDT
More quotes
Clal Biotechnology Industries Ltd (CBI) is an Israel-based biotechnology investment company. CBI's investments are targeted at bio-pharmaceutical companies, which are at different stages of research and development. The Company is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII) that is part of IDB group. Clal Biotechnology Industries Ltd. has a number of portfolio companies, namely Andromeda Biotech Ltd., engaged in the field of type 1 diabetes; D-Pharm Ltd and Trombutech, engaged in the field of ischemic stroke; Mediwound Ltd., engaged in burn and wound management; Biokine Ltd, Biocancell Ltd and CureTech, engaged in the field of cancer; Braintact, engaged in the CNS field and Polyheal Ltd, engaged in wound management, among others.
Sector
Investment Holding Companies
| 1st Jan change | Capi. | |
|---|---|---|
| +13.60% | 18.59M | |
| +16.29% | 74.61B | |
| +52.89% | 16.66B | |
| +4.00% | 15.56B | |
| +7.08% | 13.66B | |
| -0.58% | 12.18B | |
| +9.84% | 12.06B | |
| +6.24% | 10.96B | |
| +31.64% | 9.95B | |
| -1.71% | 9.59B |
- Stock Market
- Equities
- CBI Stock
